Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis
- PMID: 34453964
- DOI: 10.1016/j.jhep.2021.08.013
Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis
Conflict of interest statement
Conflict of interest Rajiv Jalan has research collaborations with Takeda, and Yaqrit, and consults for Yaqrit. Rajiv Jalan is the founder of Yaqrit Limited, which is developing UCL inventions for treatment of patients with cirrhosis. Rajiv Jalan is an inventor of ornithine phenylacetate, which was licensed by UCL to Mallinckrodt. He is also the inventor of Yaq-001, DIALIVE and Yaq-005, the patents for which have been licensed by his University into a UCL spinout company, Yaqrit Ltd. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".J Hepatol. 2022 Feb;76(2):487-488. doi: 10.1016/j.jhep.2021.11.002. Epub 2021 Nov 10. J Hepatol. 2022. PMID: 34774640 No abstract available.
Comment on
-
Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score.J Hepatol. 2021 Jun;74(6):1325-1334. doi: 10.1016/j.jhep.2020.12.033. Epub 2021 Jan 24. J Hepatol. 2021. PMID: 33503489
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
